Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.82
- Piotroski Score 3.00
- Grade Buy
- Symbol (BNTX)
- Company BioNTech SE
- Price $113.14
- Changes Percentage (4.54%)
- Change $4.91
- Day Low $107.41
- Day High $114.32
- Year High $131.49
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
- Last Earnings 04/27/2022
- Ex-Dividend for 5/16 Dividend 06/02/2022
- Dividend Payable 06/17/2022
- Today N/A
- Next Earnings (Estimated) 03/10/2025
- Fiscal Year End N/A
- Average Stock Price Target $141.00
- High Stock Price Target $359.00
- Low Stock Price Target $95.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.51
- Trailing P/E Ratio 196.75
- Forward P/E Ratio 196.75
- P/E Growth 196.75
- Net Income $930.30 M
Income Statement
Quarterly
Annual
Latest News of BNTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is BioNTech SE (BNTX) the Best German Stock to Buy Now?
A list of the 10 Best German Stocks To Buy Now includes BioNTech SE. Germany's economy is industry-based, with manufacturing contributing significantly to its gross value. The manufacturing sector's e...
By Yahoo! Finance | 3 days ago -
BioNTech SE's Strategic Growth in Oncology and mRNA
BioNTech SE is expanding its oncology portfolio and advancing mRNA cancer vaccines, with a strong financial standing of €17.8 billion in cash and investments. The company's innovative technologies a...
By Yahoo! Finance | 1 week ago -
BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ...
The company has set aside around EUR600 million for legal disputes. Updates from the Chief Medical Officer and CEO on BNT323 in endometrial cancer, BNT327 outcomes, and rationale for biomarker-selecte...
By Yahoo! Finance | 2 weeks ago
